Ftse Mib
34.659,55
-0,29%
DAX
18.677,87
-0,45%
S&P 500
5.306,04
0,02%
NASDAQ
17.019,88
0,59%
Bitcoin
68.750,01
0,67%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Fate Therapeutics Inc (FATE) Fate Therapeutics Inc (FATE) Notizie

FATE

Fate Therapeutics (FATE)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FATE
DataOraFonteTitoloSimboloCompagnia
09/05/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FATEFate Therapeutics Inc
09/05/202422:01GlobeNewswire Inc.Fate Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
09/05/202414:30GlobeNewswire Inc.Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell ProgramNASDAQ:FATEFate Therapeutics Inc
06/05/202414:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational UpdatesNASDAQ:FATEFate Therapeutics Inc
03/05/202422:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
22/04/202422:30GlobeNewswire Inc.Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual MeetingNASDAQ:FATEFate Therapeutics Inc
03/04/202414:00GlobeNewswire Inc.Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FATEFate Therapeutics Inc
02/04/202422:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
19/03/202413:44GlobeNewswire Inc.Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private PlacementNASDAQ:FATEFate Therapeutics Inc
05/03/202422:24Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FATEFate Therapeutics Inc
04/03/202419:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:FATEFate Therapeutics Inc
01/03/202414:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming March Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
26/02/202422:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:FATEFate Therapeutics Inc
26/02/202422:01GlobeNewswire Inc.Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
15/02/202414:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
13/02/202400:06Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FATEFate Therapeutics Inc
02/02/202422:01GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
08/01/202414:00GlobeNewswire Inc.Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid TumorsNASDAQ:FATEFate Therapeutics Inc
13/12/202323:00GlobeNewswire Inc.Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:FATEFate Therapeutics Inc
28/11/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:FATEFate Therapeutics Inc
08/11/202322:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:FATEFate Therapeutics Inc
08/11/202322:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FATEFate Therapeutics Inc
08/11/202322:01GlobeNewswire Inc.Fate Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
25/10/202314:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
31/08/202314:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming September Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
08/08/202322:01GlobeNewswire Inc.Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdatesNASDAQ:FATEFate Therapeutics Inc
28/07/202314:00GlobeNewswire Inc.Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2023 Financial ResultsNASDAQ:FATEFate Therapeutics Inc
15/06/202322:06Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FATEFate Therapeutics Inc
08/06/202322:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FATEFate Therapeutics Inc
31/05/202314:00GlobeNewswire Inc.Fate Therapeutics to Present at Upcoming June Investor ConferencesNASDAQ:FATEFate Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:FATE

La tua Cronologia

TG
RAG
Radian
EU
0465T
0465T
BIT
3LPA
Exchange Traded
BIT
FNM
FNM
BIT
UB4Q6X
Unicredit Bank
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network